Literature DB >> 2303360

DNA typing for class II HLA antigens with allele-specific or group-specific amplification. I. Typing for subsets of HLA-DR4.

X J Gao1, M Fernandez-Vina, W Shumway, P Stastny.   

Abstract

DNA sequences that distinguish the subsets of HLA-DR4 are also found on several other alleles. This makes typing of heterozygotes with oligonucleotide probes quite impractical. We have therefore developed a procedure in which, in a first step, DNA of the genes to be analyzed is amplified selectively, using group-specific primers. In the case of DR4-DRB1, a primer matching codons 5 to 13 when used in the polymerase chain reaction resulted in products that were entirely suitable for typing for the DR4 subsets. Using appropriate probes, eight distinct subsets were identified. However, only six of them were represented in a normal North American Caucasian panel. In conjunction with a method for rapid DNA extraction, the procedure offers a simple, highly specific and reproducible method for determining subtypes of HLA-DR4 that at present cannot be recognized by serologic methods.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303360     DOI: 10.1016/0198-8859(90)90094-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain.

Authors:  E W Petersdorf; A G Smith; E M Mickelson; P J Martin; J A Hansen
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of Brazil.

Authors:  J R Moraes; M E Moraes; M Fernandez-Vina; L A Diaz; H Friedman; I T Campbell; R R Alvarez; S A Sampaio; E A Rivitti; P Stastny
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

3.  Heterogeneity in HLA-DR2-related DR,DQ haplotypes in eight populations of Asia-Oceania.

Authors:  X J Gao; S W Serjeantson
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

4.  Sequence analysis and HLA-DR genotyping of a novel HLA-DRw14 allele.

Authors:  F Obata; I Ito; K Ito; A Abe; M Ohkubo; K Onda; Y G Yang; K Watanabe; N Kashiwagi
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

5.  Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene.

Authors:  Maurizio Viale; Maria A Mariggiò; Massimo Ottone; Barbara Chiavarina; Angela Vinella; Claudia Prevosto; Carlo Dell'Erba; Giovanni Petrillo; Marino Novi
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

6.  A novel HLA-DRB1 allele (DRB1*0417) in South American Indians.

Authors:  S Zhang; M Fernandez-Vina; M Falco; M Cerná; E Raimondi; P Stastny
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

7.  Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups.

Authors:  M A Fernandez-Viña; X J Gao; M E Moraes; J R Moraes; I Salatiel; S Miller; J Tsai; Y P Sun; J B An; Z Layrisse
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

8.  Molecular analysis of HLA-DR beta and DQ beta polymorphism in Chinese with rheumatoid arthritis.

Authors:  J Molkentin; P K Gregersen; X Lin; N Zhu; Y Wang; Y Wang; S Chen; S Chen; L A Baxter-Lowe; J Silver
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

9.  HLA-DP/DR interaction in early onset pauciarticular juvenile chronic arthritis.

Authors:  C Paul; U Schoenwald; H Truckenbrodt; M P Bettinotti; G Brünnler; E Keller; C Nevinny-Stickel; Z Yao; E D Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

10.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.